Ruxolitinib

Brand names: Jakafi, Jakafi Xr · Active ingredient: Ruxolitinib

In short: JAKAFI/JAKAFI XR is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF in adults. JAKAFI/JAKAFI XR is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate re

Forms & strengthsJAKAFI: 5 mg tablets - round and white with "INCY" on one side and "5" on the other. 10 mg tablets - round and white with "INCY" on one side and "10" on the other. 15 mg tablets - oval and white with "INCY" on one side and "15" on the other. …
LabelIncyte Corporation
Label updatedAug 03, 2026

What is Ruxolitinib used for?

JAKAFI/JAKAFI XR is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF in adults.

JAKAFI/JAKAFI XR is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

JAKAFI/JAKAFI XR is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.

JAKAFI/JAKAFI XR is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Ruxolitinib dosage

Prior to JAKAFI/JAKAFI XR treatment:

Perform a complete blood count (CBC) .

Inquire about past infections, including tuberculosis, herpes simplex, herpes zoster, and hepatitis B .

During treatment with JAKAFI/JAKAFI XR:

Perform a CBC every 2 to 4 weeks until doses are stabilized, and then as clinically indicated .

Assess lipid parameters approximately 8 to 12 weeks following initiation of JAKAFI/JAKAFI XR therapy

.

The recommended starting dose of JAKAFI/JAKAFI XR is based on platelet count (Table 1). Doses may be titrated based on safety and efficacy.

Platelet Count | JAKAFI Starting Dose | JAKAFI XR Starting Dose

Greater than 200 x 109/L | 20 mg orally twice daily | 44 mg orally once daily

100 x 109/L to 200 x 109/L | 15 mg orally twice daily | 33 mg orally once daily

50 x 109/L to less than 100 x 109/L | 5 mg orally twice daily | 11 mg orally once daily

Dose Reductions

JAKAFI dose reductions should be considered if the platelet counts decrease as outlined in Table 2 with the goal of avoiding dose interruptions for thrombocytopenia.

Dose at Time of Platelet Decline

Platelet Count | 25 mg

Twice Daily | 20 mg

Twice Daily | 15 mg

Twice Daily | 10 mg

Twice Daily | 5 mg

Twice Daily

New

Dose | New

Dose | New

Dose | New

Dose | New

Dose

100 to less than

125 x 109/L | 20 mg

twice daily | 15 mg

twice daily | No change | No change | No change

75 to less than

100 x 109/L | 10 mg

twice daily | 10 mg

twice daily | 10 mg

twice daily | No change | No change

50 to less than

75 x 109/L | 5 mg

twice daily | 5 mg

twice daily | 5 mg

twice daily | 5 mg

twice daily | No change

Less than 50 x 109/L | Hold | Hold | Hold | Hold | Hold

JAKAFI XR dose reductions should be considered if the platelet counts decrease as outlined in Table 3, with the goal of avoiding dose interruptions for thrombocytopenia.

Dose at Time of Platelet Decline

Platelet Count | 55 mg

Once Daily | 44 mg

Once Daily | 33 mg

Once Daily | 22 mg

Once Daily | 11 mg

Once Daily

New

Dose | New

Dose | New

Dose | New

Dose | New

Dose

100 to less than

125 x 109/L | 44 mg

once daily | 33 mg

once daily | No change | No change | No change

75 to less than

100 x 109/L | 22 mg

once daily | 22 mg

once daily | 22 mg

once daily | No change | No change

50 to less than

75 x 109/L | 11 mg

once daily | 11 mg

once daily | 11 mg

once daily | 11 mg

once daily | No change

Less than 50 x 109/L | Hold | Hold | Hold | Hold | Hold

Treatment Interruption and Restarting Dosing

Interrupt treatment for platelet counts less than 50 x 109/L or absolute neutrophil count (ANC) less than 0.5 x 109/L.

After recovery of platelet counts above 50 × 109/L and ANC above 0.75 × 109/L, dosing may be restarted. When restarting JAKAFI, begin with a dose that is at least 5 mg twice daily below the dose at interruption. …

How to take Ruxolitinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Thrombocytopenia, Anemia, and Neutropenia

Inform patients that JAKAFI/JAKAFI XR is associated with thrombocytopenia, anemia and neutropenia, and of the need to monitor CBC before and during treatment. Advise patients to observe for and report bleeding .

Infections

Inform patients of the signs and symptoms of infection and to report any such signs and symptoms promptly.

Inform patients regarding the early signs and symptoms of herpes zoster and of PML, and advise patients to seek the advice of a clinician if such symptoms are observed .

Symptom Exacerbation Following Interruption or Discontinuation of Treatment

Inform patients that after discontinuation of treatment, signs and symptoms from myeloproliferative neoplasms may flare. Instruct patients not to interrupt or discontinue JAKAFI/JAKAFI XR therapy without consulting their healthcare provider .

Non-Melanoma Skin Cancer

Inform patients that JAKAFI/JAKAFI XR may increase their risk of certain NMSCs. …

Warnings & precautions

Do not take this medicine if: None.

Treatment with JAKAFI/JAKAFI XR can cause thrombocytopenia, anemia, and neutropenia .

Manage thrombocytopenia by reducing the dose or temporarily interrupting JAKAFI/JAKAFI XR. Platelet transfusions may be necessary .

Patients developing anemia may require blood transfusions and/or dose modifications of JAKAFI/JAKAFI XR.

Severe neutropenia (ANC less than 0.5 × 109/L) was generally reversible by withholding JAKAFI/JAKAFI XR until recovery.

Perform a pre-treatment CBC and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated .

Serious bacterial, mycobacterial, fungal, and viral infections have occurred . Delay starting therapy with JAKAFI/JAKAFI XR until active serious infections have resolved. Observe patients receiving JAKAFI/JAKAFI XR for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines.

Tuberculosis

Tuberculosis infection has been reported in patients receiving JAKAFI. Observe patients receiving JAKAFI/JAKAFI XR for signs and symptoms of active tuberculosis and manage promptly.

Prior to initiating JAKAFI/JAKAFI XR, patients should be evaluated for tuberculosis risk factors, and those at higher risk should be tested for latent infection. Risk factors include, but are not limited to, prior residence in or travel to countries with a high prevalence of tuberculosis, close contact with a person with active tuberculosis, and a history of active or latent tuberculosis where an adequate course of treatment cannot be confirmed.

For patients with evidence of active or latent tuberculosis, consult a physician with expertise in the treatment of tuberculosis before starting JAKAFI/JAKAFI XR. …

Ruxolitinib side effects

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

Thrombocytopenia, Anemia and Neutropenia

Risk of Infection

Symptom Exacerbation Following Interruption or Discontinuation of Treatment

Non-Melanoma Skin Cancer

Lipid Elevations

Major Adverse Cardiovascular Events (MACE)

Thrombosis

Secondary Malignancies

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of JAKAFI XR has been established from adequate and well-controlled studies of JAKAFI in adult patients with myelofibrosis, polycythemia vera, and adult and pediatric patients with acute and chronic graft-versus-host-disease . Below is a display of the adverse reactions of JAKAFI in these adequate and well-controlled studies.

Myelofibrosis

The safety of JAKAFI was assessed in 617 patients in 6 clinical studies with a median duration of follow-up of 10.9 months, including 301 patients with MF in 2 Phase 3 studies.

In these 2 Phase 3 studies, patients had a median duration of exposure to JAKAFI of 9.5 months (range: 0.5 to 17 months), with 89% of patients treated for more than 6 months and 25% treated for more than 12 months. …

Drug interactions

Fluconazole

Concomitant use of JAKAFI/JAKAFI XR with fluconazole increases ruxolitinib exposure , which may increase the risk of exposure-related adverse reactions. Avoid concomitant use of JAKAFI/JAKAFI XR with fluconazole doses of greater than 200 mg daily. Reduce the JAKAFI/JAKAFI XR dosage when used concomitantly with fluconazole doses of less than or equal to 200 mg .

Strong CYP3A4 Inhibitors

Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inhibitors increases ruxolitinib exposure , which may increase the risk of exposure-related adverse reactions. Reduce the JAKAFI/JAKAFI XR dosage when used concomitantly with strong CYP3A4 inhibitors except in patients with aGVHD or cGVHD .

Strong CYP3A4 Inducers

Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure , which may reduce efficacy of JAKAFI/JAKAFI XR. Monitor patients frequently and adjust the JAKAFI/JAKAFI XR dose based on safety and efficacy .

About this medicine

Ruxolitinib phosphate is a kinase inhibitor with the chemical name (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and a molecular weight of 404.36. Ruxolitinib phosphate has the following structural formula:

Ruxolitinib phosphate is a white to off-white to light pink powder and is soluble in aqueous buffers across a pH range of 1 to 8.

JAKAFI (ruxolitinib) tablets are for oral administration. Each tablet contains 5 mg, 10 mg, 15 mg, 20 mg, or 25 mg of ruxolitinib free base, equivalent to 6.6 mg, 13.2 mg, 19.8 mg, 26.4 mg, or 33 mg of ruxolitinib phosphate, respectively, and the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium starch glycolate.

JAKAFI XR (ruxolitinib) extended-release tablets are for oral administration. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f1c82580-87ae-11e0-bc84-0002a5d5c51b. Read the full official label on DailyMed.